Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill
melanoma cells. Interferon alfa may interfere with the growth of tumor cells. It is not yet
known whether combination chemotherapy plus interleukin-2 and interferon alfa is more
effective than combination chemotherapy alone for metastatic melanoma.
PURPOSE: Randomized phase III trial to compare combination chemotherapy with or without
interleukin-2 and interferon alfa in treating patients who have metastatic melanoma that
cannot be treated by surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI) Southwest Oncology Group